SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

EBioMedicine

Volumn 20, Issue , 2017, Pages 137-149

  Xu, Liang ^a   Nagata, Naoto ^a   Nagashimada, Mayumi ^a   Zhuge, Fen ^a   Ni, Yinhua ^a   Chen, Guanliang ^a   Mayoux, Eric ^b   Kaneko, Shuichi ^c   Ota, Tsuguhito ^a,c  

^a KANAZAWA UNIVERSITY   (Japan)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Brown adipose tissue; Energy metabolism; Inflammation; Macrophage; Obesity; Sodium glucose cotransporter 2 inhibitor

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; HUMAN INSULIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; FATTY ACID; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL TISSUE; ARTICLE; CALORIMETRY; CHRONIC INFLAMMATION; CONTROLLED STUDY; FATTY ACID OXIDATION; FATTY LIVER; FLUORESCENCE ACTIVATED CELL SORTING; FOOD INTAKE; GLUCOSE TOLERANCE TEST; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; INDIRECT CALORIMETRY; INSULIN RESISTANCE; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THERMOGENESIS; WEIGHT GAIN; WESTERN BLOTTING; ADIPOSE TISSUE; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; DRUG EFFECTS; ENERGY METABOLISM; IMMUNOLOGY; INFLAMMATION; LIPID DIET; MACROPHAGE ACTIVATION; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; SKELETAL MUSCLE;

ADIPOSE TISSUE; ADIPOSITY; ANIMALS; BENZHYDRYL COMPOUNDS; BIOMARKERS; BODY WEIGHT; DIET, HIGH-FAT; ENERGY METABOLISM; FATTY ACIDS; FATTY LIVER; GLUCOSE; GLUCOSIDES; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; MUSCLE, SKELETAL; OBESITY; OXIDATION-REDUCTION; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85020077721     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2017.05.028     Document Type: Article

References (46)

1. Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., Maratos-Flier, E., Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5:6 (2007), 426–437, 10.1016/j.cmet.2007.05.002.
2. Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thevenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W.J., et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med. 21:5 (2015), 512–517, 10.1038/nm.3828.
3. Brestoff, J.R., Kim, B.S., Saenz, S.A., Stine, R.R., Monticelli, L.A., Sonnenberg, G.F., Thome, J.J., Farber, D.L., Lutfy, K., Seale, P., et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519:7542 (2015), 242–246, 10.1038/nature14115.
4. Cohen, P., Levy, J.D., Zhang, Y., Frontini, A., Kolodin, D.P., Svensson, K.J., Lo, J.C., Zeng, X., Ye, L., Khandekar, M.J., et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell 156:1–2 (2014), 304–316, 10.1016/j.cell.2013.12.021.
5. Devenny, J.J., Godonis, H.E., Harvey, S.J., Rooney, S., Cullen, M.J., Pelleymounter, M.A., Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (dio) rats. Obesity 20:8 (2012), 1645–1652, 10.1038/oby.2012.59.
6. Ferrannini, E., Solini, A., SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat. Rev. Endocrinol. 8:8 (2012), 495–502, 10.1038/nrendo.2011.243.
7. Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U.C., Woerle, H.J., Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124:2 (2014), 499–508, 10.1172/JCI72227.
8. Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T.R., Muscelli, E., Shift to fatty substrate utilization in response to sodium-glucose votransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65:5 (2016), 1190–1195, 10.2337/db15-1356.
9. Fisher, F.M., Kleiner, S., Douris, N., Fox, E.C., Mepani, R.J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J.S., Maratos-Flier, E., et al. FGF21 regulates pgc-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26:3 (2012), 271–281, 10.1101/gad.177857.111.
10. Gowans, G.J., Hawley, S.A., Ross, F.A., Hardie, D.G., Amp is a true physiological regulator of amp-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab. 18:4 (2013), 556–566, 10.1016/j.cmet.2013.08.019.
11. Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D.E., Bakker, R.A., Mark, M., Klein, T., Eickelmann, P., Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14:1 (2012), 83–90, 10.1111/j.1463-1326.2011.01517.x.
12. Hardie, D.G., AMPK-sensing energy while talking to other signaling pathways. Cell Metab. 20:6 (2014), 939–952, 10.1016/j.cmet.2014.09.013.
13. Hardie, D.G., Schaffer, B.E., Brunet, A., AMPK: an energy-sensing pathway with multiple inputs and outputs. Trends Cell Biol. 26:3 (2016), 190–201, 10.1016/j.tcb.2015.10.013.
14. +/glucose co-transporter inhibitor canagliflozin activates AMP-activated protein kinase by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 65:9 (2016), 2784–2794, 10.2337/db16-0058.
15. Hotamisligil, G.S., Inflammation and metabolic disorders. Nature 444:7121 (2006), 860–867, 10.1038/nature05485.
16. Hui, X., Gu, P., Zhang, J., Nie, T., Pan, Y., Wu, D., Feng, T., Zhong, C., Wang, Y., Lam, K.S., et al. Adiponectin enhances cold-induced browning of subcutaneous adipose tissue via promoting M2 macrophage proliferation. Cell Metab. 22:2 (2015), 279–290, 10.1016/j.cmet.2015.06.004.
17. Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. Endocrine regulation of the fasting response by pparalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5:6 (2007), 415–425, 10.1016/j.cmet.2007.05.003.
18. Inzucchi, S.E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.M., Woerle, H.J., Broedl, U.C., Johansen, O.E., SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab. Vasc. Dis. Res. 12:2 (2015), 90–100, 10.1177/1479164114559852.
19. Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., Sandusky, G.E., Hammond, L.J., Moyers, J.S., Owens, R.A., et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115:6 (2005), 1627–1635, 10.1172/JCI23606.
20. Kitade, H., Sawamoto, K., Nagashimada, M., Inoue, H., Yamamoto, Y., Sai, Y., Takamura, T., Yamamoto, H., Miyamoto, K., Ginsberg, H.N., et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes 61:7 (2012), 1680–1690, 10.2337/db11-1506/-/DC1.
21. Lumeng, C.N., Bodzin, J.L., Saltiel, A.R., Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117:1 (2007), 175–184, 10.1172/JCI29881.
22. Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G.M., Unger, R.H., Insulin within islets is a physiologic glucagon release inhibitor. J. Clin. Invest. 74:6 (1984), 2296–2299, 10.1172/JCI111658.
23. Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T.V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M.A., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 124:2 (2014), 509–514, 10.1172/JCI70704.
24. Nakano, S., Katsuno, K., Isaji, M., Nagasawa, T., Buehrer, B., Walker, S., Wilkison, W.O., Cheatham, B., Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice. J. Clin. Exp. Hepatol. 5:3 (2015), 190–198, 10.1016/j.jceh.2015.02.005.
25. Neschen, S., Scheerer, M., Seelig, A., Huypens, P., Schultheiss, J., Wu, M., Wurst, W., Rathkolb, B., Suhre, K., Wolf, E., et al. Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice. Diabetes 64:1 (2015), 284–290, 10.2337/db14-0393.
26. Nguyen, K.D., Qiu, Y., Cui, X., Goh, Y.P., Mwangi, J., David, T., Mukundan, L., Brombacher, F., Locksley, R.M., Chawla, A., Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 480:7375 (2011), 104–108, 10.1038/nature10653.
27. Ni, Y., Nagashimada, M., Zhan, L., Nagata, N., Kobori, M., Sugiura, M., Ogawa, K., Kaneko, S., Ota, T., Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, beta-cryptoxanthin. Endocrinology 156:3 (2015), 987–999, 10.1210/en.2014-1776.
28. Ni, Y., Nagashimada, M., Zhuge, F., Zhan, L., Nagata, N., Tsutsui, A., Nakanuma, Y., Kaneko, S., Ota, T., Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: a comparison with vitamin e. Sci. Rep., 5, 2015, 17192, 10.1038/srep17192.
29. Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M., Otsu, M., Hara, K., Ueki, K., Sugiura, S., et al. CD8 + effector t cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 15:8 (2009), 914–920, 10.1038/nm.1964.
30. Obata, A., Kubota, N., Kubota, T., Iwamoto, M., Sato, H., Sakurai, Y., Takamoto, I., Katsuyama, H., Suzuki, Y., Fukazawa, M., et al. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology 157:3 (2016), 1029–1042, 10.1210/en.2015-1588.
31. Odegaard, J.I., Ricardo-Gonzalez, R.R., Goforth, M.H., Morel, C.R., Subramanian, V., Mukundan, L., Eagle, A.R., Vats, D., Brombacher, F., Ferrante, A.W., et al. Macrophage-specific ppargamma controls alternative activation and improves insulin resistance. Nature 447:7148 (2007), 1116–1120, 10.1038/nature05894.
32. Ota, T., Gayet, C., Ginsberg, H.N., Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J. Clin. Invest. 118:1 (2008), 316–332, 10.1172/JCI32752.
33. Patsouris, D., Li, P.P., Thapar, D., Chapman, J., Olefsky, J.M., Neels, J.G., Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 8:4 (2008), 301–309, 10.1016/j.cmet.2008.08.015.
34. Qiang, S., Nakatsu, Y., Seno, Y., Fujishiro, M., Sakoda, H., Kushiyama, A., Mori, K., Matsunaga, Y., Yamamotoya, T., Kamata, H., et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol. Metab. Syndr., 7, 2015, 104, 10.1186/s13098-015-0102-8.
35. Qiu, Y., Nguyen, K.D., Odegaard, J.I., Cui, X., Tian, X., Locksley, R.M., Palmiter, R.D., Chawla, A., Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell 157:6 (2014), 1292–1308, 10.1016/j.cell.2014.03.066.
36. Rieg, T., Masuda, T., Gerasimova, M., Mayoux, E., Platt, K., Powell, D.R., Thomson, S.C., Koepsell, H., Vallon, V., Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am. J. Physiol. Renal Physiol. 306:2 (2014), F188–F193, 10.1152/ajprenal.00518.2013.
37. Rossetti, L., Smith, D., Shulman, G.I., Papachristou, D., DeFronzo, R.A., Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J. Clin. Invest. 79:5 (1987), 1510–1515, 10.1172/JCI112981.
38. Sell, H., Habich, C., Eckel, J., Adaptive immunity in obesity and insulin resistance. Nat. Rev. Endocrinol. 8:12 (2012), 709–716, 10.1038/nrendo.2012.114.
39. Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol. 715:1–3 (2013), 246–255, 10.1016/j.ejphar.2013.05.014.
40. Thomas, L., Grempler, R., Eckhardt, M., Himmelsbach, F., Sauer, A., Klein, T., Eickelmann, P., Mark, M., Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes. Metab. 14:1 (2012), 94–96, 10.1111/j.1463-1326.2011.01518.x.
41. Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K.A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S.C., Rieg, T., Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am. J. Physiol. Renal Physiol. 304:2 (2013), F156–F167, 10.1152/ajprenal.00409.2012.
42. Wan, J., Benkdane, M., Teixeira-Clerc, F., Bonnafous, S., Louvet, A., Lafdil, F., Pecker, F., Tran, A., Gual, P., Mallat, A., et al. M2 kupffer cells promote M1 kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 59:1 (2014), 130–142, 10.1002/hep.26607.
43. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., Ferrante, A.W. Jr., Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112:12 (2003), 1796–1808, 10.1172/JCI19246.
44. Yamauchi, T., Kadowaki, T., Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int. J. Obes. 32:Suppl. 7 (2008), S13–S18, 10.1038/ijo.2008.233.
45. Yokono, M., Takasu, T., Hayashizaki, Y., Mitsuoka, K., Kihara, R., Muramatsu, Y., Miyoshi, S., Tahara, A., Kurosaki, E., Li, Q., et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur. J. Pharmacol. 727 (2014), 66–74, 10.1016/j.ejphar.2014.01.040.
46. Zhuge, F., Ni, Y., Nagashimada, M., Nagata, N., Xu, L., Mukaida, N., Kaneko, S., Ota, T., DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization. Diabetes 65:10 (2016), 2966–2979, 10.2337/db16-0317.